T-cell therapy developer Adaptimmune Therapeutics raised $65.9 million through an underwritten public offering of American depositary shares.
The company,which recently opened its novel U.
S. headquarters at the Philadelphia Navy Yard, sold 15.7 million shares at $4.20 per share. That figure included 1.4 million shares sold by underwriters to cover overallotments.
Adaptimmune (NASDAQ: ADAP) plans to use the $61.8 million in net proceeds from the offering to advance its pipeline of SPEAR T-cell candidates…
Source: bizjournals.com